Matrix P and Matrix P plus tissue-engineered pulmonary valves have a high failure rate (52%) due to severe inflammation and fibrosis, and their use for pulmonary valve replacement is not supported.
No takes yet. Share an insight, caveat, or question.
Caution against Matrix P valve use is warranted; Level 3 data leaves randomized durability trials open.
Voges et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: